TGBA01AD

{{Short description|Investigational antidepressant drug}}

{{cs1 config|name-list-style=vanc}}

{{Drugbox

| Verifiedfields =

| Watchedfields =

| verifiedrevid =

| IUPAC_name =

| image =

| width =

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration = By mouth

| bioavailability = 17%

| protein_bound =

| metabolism =

| elimination_half-life = 4 hours

| excretion =

| CAS_number_Ref =

| CAS_number =

| CAS_supplemental =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank_Ref =

| DrugBank =

| ChemSpiderID_Ref =

| ChemSpiderID =

| synonyms = FKB01MD

| C= | H= | N= | O=

| SMILES =

| StdInChI_Ref =

| StdInChI =

| StdInChIKey_Ref =

| StdInChIKey =

}}

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT_1A and 5-HT_1D receptor agonist, and 5-HT₂ receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.{{cite journal|title=Drugs in Clinical Development for Major Depressive Disorder|journal=Pharmaceutical Medicine|volume=27|issue=1|year=2013|pages=35–42|issn=1178-2595|doi=10.1007/s40290-013-0007-5|s2cid=16286323}}{{cite web | work = Fabre-Kramer | url = http://www.fabrekramer.com/?page_id=66 | title = FKB01MD }}{{cite journal | vauthors = Żmudzka E, Sałaciak K, Sapa J, Pytka K | title = Serotonin receptors in depression and anxiety: Insights from animal studies | journal = Life Sciences | volume = 210 | issue = | pages = 106–124 | date = October 2018 | pmid = 30144453 | doi = 10.1016/j.lfs.2018.08.050 | s2cid = 52090587 }} It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.{{cite web | work = AdisInsight | url = http://adisinsight.springer.com/drugs/800029513 | title = TGBA01AD | publisher = Springer Nature Switzerland AG }}